We came across FDA warning letters when reviewing regulatory documents for our Cochrane review on the influenza antivirals Tamiflu and Relenza. Specifically, a letter warned Roche, the manufacturer of Tamiflu, not to claim effects on complications such as pneumonia. This was interesting, as ameliorating or preventing complications were two of the most i…
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.